MiRNAs as circulating biomarkers for Alzheimer's disease and Parkinson's disease

Medicinal Chemistry

Volumn 12, Issue 3, 2016, Pages 217-225

  Mushtaq, Gohar ^a   Greig, Nigel H ^b   Anwar, Firoz ^a   Zamzami, Mazin A ^a   Choudhry, Hani ^a   Shaik, Munvar M ^c   Tamargo, Ian A ^b   Kamal, Mohammad A ^a,d  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^d Enzymoics   (Australia)

Author keywords

Alzheimer's disease; Biofluids; Diagnostic biomarkers; MiRNAs; Parkinson's disease; Amyloid; synuclein

Indexed keywords

MICRORNA; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; BIOPSY; BRAIN TISSUE; CEREBROSPINAL FLUID; CLINICAL OBSERVATION; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; HUMAN; NEUROIMAGING; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; SERUM; URINE; ANIMAL; BLOOD; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; BIOMARKERS; HUMANS; MICRORNAS; PARKINSON DISEASE;

EID: 84964725574     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406411666151030112140     Document Type: Article

References (84)

1. Maffioletti, E.; Tardito, D.; Gennarelli, M.; Bocchio-Chiavetto, L. Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Front. Cell. Neurosci., 2014, 8, 75.
2. Johnson, R.; Noble, W.; Tartaglia, G.G.; Buckley, N.J. Neurodegeneration as an RNA disorder. Prog. Neurobiol., 2012, 99, 293- 315.
3. Goodall, E.F.; Heath, P.R.; Bandmann, O.; Kirby, J.; Shaw, P.J. Neuronal dark matter: The emerging role of microRNAs in neurodegeneration. Front. Cell. Neurosci., 2013, 7, 178.
4. Chen, K.; Rajewsky, N. The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev. Genet., 2007, 8(2), 93- 103.
5. Cuellar, T.L.; McManus, M.T. MicroRNAs and endocrine biology. J. Endocrinol., 2005, 187(3), 327-332.
6. Lim, L.P.; Lau, N.C.; Garrett-Engele, P.; Grimson, A.; Schelter, J.M.; Castle, J. et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 2005, 433(7027), 769-773.
7. Chen, C.Z.; Li, L.; Lodish, H.F.; Bartel, D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science, 2004, 303(5654), 83-6.
8. Poy, M.N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X.; Macdonald, P.E. et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature, 2004, 432(7014), 226-30.
9. Kamal, M.A.; Mushtaq, G.; Greig, N.H. Current update on synopsis of miRNA deregulation in Neurological Disorders. CNS Neurol. Disord. Drug Targets, 2015, 13, 8.
10. Tan, L.; Yu, J.T.; Tan, L. Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases. Mol. Neurobiol., 2015, 51(3), 1249-62.
11. Krichevsky, A.M.; King, K.S.; Donahue, C.P.; Khrapko, K.; Kosik, K.S. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA, 2003, 9, 1274-1281.
12. Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T. Identification of novel genes coding for small expressed RNAs. Science, 2001, 294, 853-858.
13. Gilad, S.; Meiri, E.; Yogev, Y.; Benjamin, S.; Lebanony, D.; Yerushalmi, N.; Benjamin, H.; Kushnir, M.; Cholakh, H.; Melamed, N.; Bentwich, Z.; Hod, M.; Goren, Y.; Chajut, A. Serum microRNAs are promising novel biomarkers. PLoS One, 2008, 3, e3148.
14. Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Takeshita, F.; Matsuki, Y.; Ochiya, T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem., 2010, 285, 17442-17452.
15. Wang, G.K.; Zhu, J.Q.; Zhang, J.T.; Li, Q.; Li, Y.; He, J.; Qin, Y.W.; Jing, Q. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J., 2010, 31, 659-666.
16. Wang, K.; Zhang, S.; Weber, J.; Baxter, D.; Galas, D.J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res., 2010, 38, 7248-7259.
17. De Smaele, E.; Ferretti, E.; Gulino, A. MicroRNAs as biomarkers for CNS, cancer and other disorders. Brain Res., 2010, 1338, 100- 11.
18. Alzheimer's Association 2010 Alzheimer's Disease: Facts and Figures. Alzheimer's Association, Chicago, IL. 2010.
19. Mushtaq, G.; Khan, J.A.; Kamal, M.A. Biological Mechanisms linking Alzheimer's disease and Type 2 Diabetes Mellitus. CNS Neurol. Disord. Drug Targets, 2014, 13, 1192-1201.
20. Klein, W.L. Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimer's Dement., 2006, 2(1), 43-55.
21. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science, 2002, 298(5594), 789-791.
22. Walsh, D.M.; Selkoe, D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 2004, 44(1), 181- 193.
23. Thomas, T.; Thomas, G.; McLendon, C.; Sutton, T.; Mullan, M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature, 1996, 380(6570), 168-171.
24. Aliev, G.; Priyadarshini, M.; Reddy, V.P.; Grieg, N.H.; Kaminsky, Y.; Cacabelos, R. et al. Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease. Curr. Med. Chem., 2014, 21(19), 2208-2217.
25. Walsh, D.M.; Selkoe, D.J. A beta oligomers - A decade of discovery. J. Neurochem., 2007, 101, 1172-1184.
26. Stoicea, N.; Wilson, T.; Chandrasekhar, K.; Bergese, S.D. The Role of microRNAs as Potential Biomarkers in Central Nervous System Disorders. Int. J. Clin. Anesthesiol., 2013, 1, 1009.
27. Danborg, P.B.; Simonsen, A.H.; Waldemar, G.; Heegaard, N.H. The potential of microRNAs as biofluid markers of neurodegenerative diseases- A systematic review. Biomarkers, 2014, 19(4), 259- 68.
28. Hebert, S.S.; De Strooper, B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci., 2009, 32, 199- 206.
29. Schonrock, N.; Gotz, J. Decoding the non-coding RNAs in Alzheimer's disease. Cell Mol. Life Sci., 2012, 69, 3543-3559.
30. Hebert, S.S.; Horre, K.; Nicolai, L.; Papadopoulou, A.S.; Mandemakers, W.; Silahtaroglu, A.N. et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc. Natl. Acad. Sci. USA, 2008, 105, 6415-6420.
31. Hebert, S.S.; Horre, K.; Nicolai, L.; Bergmans, B.; Papadopoulou, A.S.; Delacourte, A.; et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol. Dis., 2009, 33, 422-428.
32. Schonrock, N.; Ke, Y.D.; Humphreys, D.; Staufenbiel, M.; Ittner, L.M.; Preiss, T. et al. Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid. PLoS One, 2010, 5(6), e11070.
33. Lukiw, W.J. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport, 2007, 18(3), 297-300.
34. Cogswell, J.P.; Ward, J.; Taylor, I.A.; Waters, M.; Shi, Y.; Cannon, B. et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis., 2008, 14, 27-41.
35. Burgos, K.; Malenica, I.; Metpally, R.; Courtright, A.; Rakela, B. et al. Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology. PLoS One, 2014, 9(5), e94839.
36. Alexandrov, P. N.; Dua, P.; Hill, J. M.; Bhattacharjee, S.; Zhao, Y.; Lukiw, W. J. MicroRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol., 2012, 3, 365-373.
37. Schipper, H.M.; Maes, O.C.; Chertkow, H.M.; Wang, E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul. Syst. Biol., 2007, 1, 263-274.
38. Wang, W.X.; Rajeev, B.W.; Stromberg, A.J.; Ren, N.; Tang, G.; Huang, Q.; et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor proteincleaving enzyme 1. J. Neurosci., 2008, 28, 1213-1223.
39. Lukiw, W.J.; Zhao, Y.; Cui, J.G. An NF-kappa-B sensitive microRNA- 146a mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J. Biol. Chem., 2008, 283, 31315-31322.
40. Sethi, P.; Lukiw, W.J. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci. Lett., 2009, 459, 100-104.
41. Müller, M.; Kuiperij, H. B.; Claassen, J. A.; Kusters, B.; Verbeek, M. M. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol. Aging, 2014, 35, 152-158.
42. Leidinger, P.; Backes, C.; Deutscher, S.; Schmitt, K.; Muller, S. C.; Frese, K., et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol., 2013, 14(7), R78.
43. Sheinerman, K. S.; Tsivinsky, V. G.; Crawford, F.; Mullan, M. J.; Abdullah, L.; Umansky, S. R. Plasma MicroRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY), 2012, 4, 590-605.
44. Geekiyanage, H.; Chan, C. MicroRNA-137/181c Regulates Serine Palmitoyltransferase and in turn Amyloid {beta}, Novel Targets in Sporadic Alzheimer's Disease. J. Neurosci., 2001, 31, 14820- 14830.
45. Geekiyanage, H.; Jicha, G.A.; Nelson, P.T.; Chan, C. Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease. Exp. Neurol., 2012, 235(2), 491-496.
46. Kumar, P.; Dezso, Z.; MacKenzie, C.; Oestreicher, J.; Agoulnik, S.; et al. Circulating miRNA Biomarkers for Alzheimer's Disease. PLoS One, 2013, 8(7), e69807.
47. Hirtz, D.; Thurman, D.J.; Gwinn-Hardy, K.; Mohamed, M.; Chaudhuri, A.R.; Zalutsky, R. How common are the "common" neurologic disorders? Neurology, 2007, 68, 326-337.
48. Thomas, B.; Beal, M.F. Parkinson's disease. Hum. Mol. Genet., 2007, 16(S2), R183-R194.
49. Goetz, C.G. The history of Parkinson's disease: Early clinical descriptions and neurological therapies. Cold Spring Harb. Perspect. Med., 2011, 1(1), a008862.
50. Shtilbans, A.; Henchcliffe, C. Biomarkers in Parkinson's disease: An update. Curr. Opin. Neurol., 2012, 25, 460-465.
51. Schapira, A.H. Pathogenesis of Parkinson's disease. Baillieres. Clin. Neurol., 1997, 6, 15-36.
52. Mouradian, M.M. MicroRNAs in Parkinson's disease. Neurobiol. Dis., 2012, 46, 279-284.
53. Ferrer, I.; Martinez, A.; Blanco, R.; Dalfo, E.; Carmona, M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: Preclinical Parkinson disease. J. Neural. Transm., 2011, 118, 821-839.
54. Maciotta, S.; Meregalli, M.; Torrente, Y. The involvement of microRNAs in neurodegenerative diseases. Front. Cell Neurosci., 2013, 7, 265.
55. Grünblatt, E. Parkinson's disease: Molecular risk factors. Parkinsonism Relat. Disord., 2012, 18(Suppl 1), S45-S48.
56. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
57. Sotiriou, S.; Gibney, G.; Baxevanis, A.D.; Nussbaum, R.L. A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci. Lett., 2009, 461, 196-201.
58. Doxakis, E. Post- Transcriptional regulation of alpha-synuclein expression by miR-7 and miR-153. J. Biol. Chem., 2010, 285, 12726-12734.
59. Junn, E.; Lee, K.W.; Jeong, B.S.; Chan, T.W.; Im, J.Y.; Mouradian, M.M. Repression of alpha- synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 13052- 13057.
60. Alvarez-Erviti, L.; Seow, Y.; Schapira, A.H.; Rodriguez-Oroz, M.C.; Obeso, J.A.; Cooper, J.M. Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease. Cell Death Dis., 2013, 4, e545.
61. Winslow, A.R.; Rubinsztein, D.C. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy, 2011, 7, 429-431.
62. Margis, R.; Margis, R.; Rieder, C.R. Identification of blood microRNAs associated to Parkinson's disease. J. Biotechnol. 2011, 152, 96-101.
63. Cardo, L.F.; Coto, E.; DeMena, L.; Ribacoba, R.; Moris, G.; Menendez, M.; et al. Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J. Neurol., 2013, 260, 1420-1422.
64. Martins, M.; Rosa, A.; Guedes, L.; Fonseca, B.; Gotovac, K.; Violante, S.; et al. Convergence of miRNA expression profiling, - synuclein interacton and GWAS in Parkinson's disease. PLoS One, 2011, 6(10), e25443.
65. Soreq, L.; Salomonis, N.; Bronstein, M.; Greenberg, D.; Israel, Z.; Bergman, H.; et al. Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front. Mol. Neurosci., 2013, 6, 10.
66. Kim, J.; Inoue, K.; Ishii, J.; Vanti, W.B.; Voronov, S.V.; Murchison, E.; et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science, 2007, 317, 1220-1224.
67. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; Watanabe, M.; Takeda, A. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41, 1303-1307.
68. Simon-Sanchez, J.; Schulte, C.; Bras, J.M.; Sharma, M.; Gibbs, J.R.; Berg, D.; Paisan-Ruiz, C.; Lichtner, P.; Scholz, S.W.; Hernandez, D.G. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet., 2009, 41, 1308- 1312.
69. Lin, X.; Parisiadou, L.; Gu, X.L.; Wang, L.; Shim, H.; Sun, L.; Xie, C.; Long, C.X.; Yang, W.J.; Ding, J. et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced byParkinson's-disease-related mutant alpha-synuclein. Neuron, 2009, 64, 807-827.
70. Cho, H.J.; Liu, G.; Jin, S.M.; Parisiadou, L.; Xie, C.; Yu, J., et al. MicroRNA-205 regulates the expression of Parkinson's diseaserelated leucine-rich repeat kinase 2 protein. Hum. Mol. Genet., 2013, 22(3), 608-20.
71. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. Lancet, 2011, 377, 1019-1031.
72. Becker, R.E.; Seeman, M.V.; Greig, N.H.; Lahiri, D.K. What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general? Lancet Psychiatry, 2015, 2(8), 756-64.
73. Becker, R.E.; Greig, N.H.; Giacobini, E.; Schneider, L.S.; Ferrucci, L. A new roadmap for drug development for Alzheimer's disease. Nat. Rev. Drug Discov., 2014, 13(2), 156.
74. Dougall, N.J.; Bruggink, S.; Ebmeier, K.P. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am. J. Geriatr. Psychiatry, 2004, 12, 554-570.
75. Nordberg, A. Dementia in 2014. Towards early diagnosis in Alzheimer disease. Nat. Rev. Neurol., 2015, 11(2), 69-70.
76. Patwardhan, M.B.; McCrory, D.C.; Matchar, D.B.; Samsa, G.P.; Rutschmann, O.T. Alzheimer disease: operating characteristics of PET- A meta- Analysis. Radiology, 2004, 231, 73-80.
77. Gallivanone, F.; Rosa, P.A.; Castiglioni, I. Statistical voxel-based methods and [18F]FDG PET brain imaging: frontiers for the diagnosis of AD. Curr. Alzheimer Res., 2015 [Epub ahead of print].
78. Eldh, M.; Lotvall, J.; Malmhall, C.; Ekstrom, K. Importance of RNA isolation methods for analysis of exosomal RNA: Evaluation of different methods. Mol. Immunol., 2012, 50, 278-286.
79. Rao, P.; Benito, E.; Fischer, A. MicroRNAs as biomarkers for CNS disease. Front. Mol. Neurosci., 2013, 6, 39.
80. Burgos, K.; Javaheria, A.; Bomprezzi, R.; Ghaffari, L.; Rhodes, S.; Courtright, A. et al. Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA, 2013, 19, 712-722.
81. Rong, H.; Liu, T.; Yang, K.; Yang, H.; Wu, D.; Liao, C. et al. MicroRNA-134 plasma levels before and after treatment for bipolarmania. J. Psychiatr. Res., 2011, 45, 92-95.
82. Ioannidis, J.; Allison, D.; Ball, C.; Coulibaly, I.; Cui, X.; Culhane, A. et al. Repeatability of published microarray gene expression analyses. Nat. Genet., 2009, 41, 149-155.
83. Ioannidis, J.; Panagiotou, O. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta- Analyses. JAMA, 2011, 305, 2200-2210.
84. Grasso, M.; Piscopo, P.; Confaloni, A.; Denti, M.A. Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules, 2014, 19(5), 6891-910.